UBS Reduces Stake in Biotech Firm Abivax Below Reporting Threshold

UBS Group reduces its holding in Abivax below a key threshold, as the biotech firm updates its capital structure and shares decline nearly 6%.

A significant shift has occurred among the major shareholders of Abivax. The Swiss banking group UBS Group has scaled back its investment in the biotechnology company, crossing below a key regulatory threshold. This move coincides with a period of recent weakness for the company's shares on the exchange.

A Shift in Shareholder Dynamics

According to recent filings with the French Financial Markets Authority (AMF), UBS Group's holding fell below the 5% mark for both capital and voting rights on March 24, 2026. The reduction resulted from an off-market sale of shares.

Following this transaction, UBS indirectly holds 3,227,593 shares. This position equates to 4.11% of the share capital and 3.99% of the exercisable voting rights. When a major institutional investor trims its position, it often draws heightened market attention to the short-term supply of shares.

Updated Capital Structure Details

In conjunction with this shareholder change, Abivax has published current details of its capital structure. As of the reference date of February 28, 2026, the company's share capital comprised the following:

• Share Capital: 79,185,160 shares
• Theoretical Voting Rights: 81,538,485
• Exercisable Voting Rights: 81,538,485
• Capital Value: €792,028.88

This disclosure provides a fresh basis for evaluating the company. The stock closed trading on March 27 at €89.20, marking a decline of nearly 6%. The stake reduction by UBS, combined with the newly confirmed capital data, sets a new context for share price discovery in the coming weeks at the current level of approximately €89.